Due to ongoing research, newly approved therapies, and changes to clinical trial design that allow more people with MBC who have brain metastases to enroll, there are now more treatment options available. These new findings impact people with HER2-positive, hormone receptor-positive, and triple-negative MBC.
Click the links below for current research on new therapies, resources and support, and clinical trials for MBC with brain metastases.
Treating HER2+ MBC Brain Metastasis
- National Cancer Institute: Results from a clinical trial suggest that temozolomide plus ado-trastuzumab emtansine (T-DM1; Kadcyla®) may prevent new brain metastases in people with HER2+ MBC
- Cancer Today: Targeted therapy and antibody-drug conjugates are emerging treatments for brain metastases in people with HER2+ MBC
Treating Triple-Negative, Hormone Receptor-Positive, or HER2+ MBC Brain Metastasis
Resources and Support for People with MBC and Brain Metastasis
- MBCBrainMets.org: Information for people with MBC and brain metastasis, including clinical trial information
- Metastatic Breast Cancer Alliance: Read more about MBCBrainMets.org and support for people with MBC and brain metastasis here
MBC Clinical Trials
- Metastatic Trial Search: Trials Specifically for People with Brain Metastases
- Metastatic Trial Search: Additional Brain Mets Trials
Last Modified on October 1, 2024